Company intelligence / Profile preview

AdhexPharma

Ownership: Private
Development stage: Commercial

Overview

AdhexPharma is an independent pharmaceutical CDMO specializing in the development and manufacturing of transdermal patches, topical patches, and oral thin films. The company supports pharma and biotech partners from R&D through commercial manufacturing under cGMP conditions. It has over 40 years of experience in drug delivery systems with more than 15 ongoing development projects and produces over 100 million units annually. Notable collaborations include production of Zeqmelit® for AcuCort targeting acute/allergic reactions[1][2].

Modalities: Transdermal patchTopical patchOral thin film
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

dexamethasone

Commercial

Indications: Allergic reactions, Croup, Chemotherapy-induced nausea and vomiting, COVID-19

Partnerships

AcuCortBUCCAL–PEP consortiumSantenov clusterPolepharma clusterPharma Licensing Club Germany

Beyond the preview

Go deeper on AdhexPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdhexPharma.

Explore the full profile